Revance Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Revance Therapeutics, Inc.
CEO Todd Zavodnick said the non-steroidal topical cream is poised to become a blockbuster brand.
Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.
Revance says it is still in discussions with Mylan on whether or not the pair will proceed with their collaboration on a biosimilar version of Botox, despite an extended deadline for a commitment on the deal having passed on 30 April.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
- Site Specific
- Topical Delivery
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Essentia Biosystems, Inc.